TABLE 46Utility regression estimates

ParameterEstimateSE95% confidence limitsZProbability > |Z|
Intercept0.88620.01820.85060.921748.82<.0001
HAQ−0.23170.0248−0.2803−0.1831−9.35<.0001
PASI−0.00250.0015−0.00540.0004−1.690.0906
HAQ × PASI−0.00390.002−0.00790−1.940.0523
No. observations used: 386
No. clusters: 138

From: Appendix 6, Clarifications from manufacturers

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.